SECURITIES LENDING TOP 10 EARNING EQUITIES - MARCH 7, 2014


US

Utilization

1     INTEROIL 97.15%
2     TWITTER 93.07%
3     JC PENNEY 96.83%
4     MYRIAD GENETICS 91.75%
5     ARENA PHARMACEUTICALS 93.85%
6     3D SYSTEMS 93.25%
7     MINDRAY MEDICAL INTL ADR CL A 90.17%
8     SEARS HOLDINGS 91.85%
9     WEIGHT WATCHERS INTERNATIONAL 95.09%
10   OPKO HEALTH 96.26%

  • Interoil ($IOC) has climbed into the top spot among U.S. top earners amid media speculation last month of a possible buy-out of the oil and gas company. Fees to borrow were trending even higher after the late-January spike. Utilization, conversely, has dropped a few percentage points since then.
  • Twitter ($TWTR) fees to borrow have dropped again from the spike in mid-February. Utilization has slid about 6% since then as the social media stock has yet to fully recover from the decline in early February.
  • The JC Penney ($JCP) stock price has been recovering since late February, while fees to borrow have been trending steadily higher. Some media have attributed the stock price gains to shrewd marketing during the recent Academy Awards, of which the department store is a sponsor.

UK

Utilization

1     BLINKX 60.01%
2     GULF KEYSTONE PETROLEUM 88.50
3     APR ENERGY 67.43%
4     TALVIVAARA MINING 85.87%
5     STOBART GROUP 65.57%
6     QUINDELL 78.00%
7     VEDANTA RESOURCES 77.30%
8     TESCO

11.99%

9     CARPETRIGHT 46.14%
10   RIO TINTO 6.33%

  • Blinkx ($BLNX.LN) remains on top in the U.K. on this week’s list. Fees to borrow continue their ascent while utilization has come down since the late-January highs.
  • Gulf Keystone ($GKP.LN) fees to borrow have been trending steadily lower since last month. Utilization has ticked upward slightly in recent days.
  • APR Energy ($APR.LN) utilization has been steadily rising since late last year. Fees to borrow have fluctuated somewhat over the same period, trending lower in more recent weeks.


Europe

Utilization

1     BANCA MONTE DEI PASCHI DI SIENA (IT) 84.61%
2     PEUGEOT (FR) 78.81%
3     THROMBOGENICS 92.30%
4     TOTAL (FR) 23.76%
5     OUTOTEC (FI) 83.23%
6     UNIBAIL RODAMCO REIT (NL) 8.89%
7     GEMALTO 88.53%
8     BANCO POPOLARE (IT) 69.77%
9     INGENICO (FR) 84.10%
10   ACERINOX (ES) 66.81%

  • This week’s list in Europe looks similar to last with the same names among the top three earners. Banca Monte Dei Paschi di Siena ($BMPS.IM) fees to borrow have been trending very gradually lower over the past month.
  • Peugeot ($UG.FP) fees to borrow were steadily rising but have been trending slightly lower in the last two weeks. Utilization has dropped upwards of 8% since February’s high.
  • ThromboGenics ($THR.BB) fees to borrow continue to trend gradually higher. Utilization is up 7% since the low point in mid-January. The biopharmaceutical company announced this week it would initiate a phase 4 study of its JETREA drug in the U.S.



Far East/Australia Pacific

Utilization

1     GUNGHO ONLINE (JP) 95.43%
2     CELLTRION (KR) 74.95%
3     BYD COMPANY H (HK) 78.09%
4     HANERGY SOLAR (HK) 80.65%
5     EVERGRANDE (HK) 80.61%
6     GREE (JP) 87.98%
7     HUISHAN DAIRY 74.60%
8     ANA HOLDINGS (JP) 92.31%
9     OLAM INTERNATIONAL (SG) 70.08%
10   MONADELPHOUS GROUP (AU) 74.28%

  • GungHo Online ($3765.JP) fees to borrow have remained virtually flat over the past month since rising again from the late-December drop. Utilization is still steady.
  • Celltrion ($068270.KS) fees to borrow have been trending slightly lower since the steady rise seen earlier in the year. Utilization has ticked down by 2% in the past month.
  • BYD Company ($1211.HK) fees to borrow have been trending lower than the peak in mid-February as the stock price as seen steady gains. Utilization hasn’t moved much in the past two months. Media have reported this week that the company has received regulatory approval to sell its electric cars in Beijing and Shanghai.

 

This is just a snapshot of the rich data and functionalities provided by DataLend. Click here for more information about DataLend's key features.



THE INFORMATION CONTAINED HEREIN IS PROPRIETARY TO EQUILEND; MAY NOT BE COPIED OR DISTRIBUTED WITHOUT THE EXPRESS CONSENT OF EQUILEND; SHALL NOT CONSTITUTE INVESTMENT ADVICE BY EQUILEND, OR ANY REPRESENTATIVE THEREOF; IS NOT WARRANTED TO BE ACCURATE, COMPLETE OR TIMELY; IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY; IS NOT INTENDED FOR TRADING PURPOSES; AND SHOULD NOT BE CONSTRUED AS EQUILEND MAKING FORECASTS, PROJECTING RETURNS OR RECOMMENDING ANY PARTICULAR COURSE OF ACTION. NEITHER EQUILEND NOR ANY REPRESENTATIVE THEREOF SHALL BE AN ADVISOR OR A FIDUCIARY OF A VISITOR TO THIS WEBSITE. EQUILEND IS NOT RESPONSIBLE OR LIABLE IN ANY WAY TO THE READER OR VISITOR, OR TO ANY PERSON, FIRM OR CORPORATION FOR ANY DAMAGES OR LOSSES ARISING FROM ANY USE OF THE INFORMATION CONTAINED HEREIN. IN CONSIDERING THE INFORMATION CONTAINED HEREIN, A VISITOR TO THIS WEBSITE DOES SO SOLELY IN RELIANCE ON THE VISITOR’S OWN JUDGMENT. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE PERFORMANCE.

DATALEND ALERTS

Sign up for weekly DataLend Top 10 email alerts



DATA ARCHIVE

March 09, 2015

March 2, 2015

February 27, 2015

January 26, 2015

November 19, 2014

November 12, 2014

November 5, 2014

October 22, 2014

October 15, 2014

October 8, 2014

September 19, 2014

September 5, 2014

August 28, 2014

August 21, 2014

July 24, 2014

June 26, 2014

June 19, 2014

June 12, 2014

June 5, 2014

May 29, 2014

May 22, 2014

May 16, 2014

May 8, 2014

May 1, 2014

April 25, 2014

April 11, 2014

April 4, 2014

March 20, 2014

March 13, 2014

March 7, 2014

February 27, 2014

February 20, 2014

February 7, 2014